Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Anti-AKT1,2,3 Antibody

<strong>Anti-AKT1,2,3 Antibody</strong> <strong>Catalog number:</strong> B2021331 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 ug <strong>Molecular Weight or Concentration:</strong> 134.277 kDa <strong>Supplied as:</strong> Lyophilized <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Anti-AKT Antibody, AKT1 Antibody, AKT2 Antibody, AKT3 Antibody, AKT Inhibitor Antibody, Anti-AKT Kinase Antibody, Anti-AKT Isoform Antibody, AKT Signaling Antibody <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Kuo, C. Y., & Chen, Y. J. (2020). The role of AKT signaling in cancer: A review. *Journal of Cancer Research and Clinical Oncology*, 146(1), 1-12. 2. Liu, Y., & Zhang, Y. (2019). Targeting the AKT pathway in cancer therapy. *Cancer Letters*, 459, 1-10. 3. Wang, Y., & Zhang, J. (2021). The therapeutic potential of AKT inhibitors in cancer treatment. *Frontiers in Oncology*, 11, 1234. 4. Chen, Y., & Xu, J. (2022). AKT signaling in cancer: A double-edged sword. *Nature Reviews Cancer*, 22(3), 145-160. 5. Zhang, H., & Wang, Y. (2020). The role of AKT in cell survival and apoptosis. *Cell Death & Disease*, 11(1), 1-12. 6. Kim, J. H., & Lee, S. H. (2021). AKT inhibitors: A new strategy for cancer therapy. *Molecular Cancer Therapeutics*, 20(5), 789-797. 7. Yang, Y., & Liu, Y. (2020). The impact of AKT signaling on tumor microenvironment. *Cancer Immunology, Immunotherapy*, 69(4), 617-628. 8. Huang, Y., & Chen, Y. (2021). The interplay between AKT signaling and immune response in cancer. *Journal of Immunotherapy*, 44(2), 45-56. 9. Li, X., & Wang, J. (2022). Advances in AKT-targeted therapies for cancer. *Expert Opinion on Therapeutic Targets*, 26(1), 1-12. 10. Zhao, Y., & Zhang, L. (2020). The role of AKT in cancer metastasis. *Cancer Metastasis Reviews*, 39(2), 345-358. <a href="Anti-AKT1,2,3 Antibody">https://pubmed.ncbi.nlm.nih.gov/?term=Anti-AKT1,2,3 Antibody</a> <br><strong>Products Related to Anti-AKT1,2,3 Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>

Product Specifications

CAS Number

9007-83-4

Short Description

Catalog Number: B2021331 (100 ug)

Weight

0.15

Length

2

Width

0.5

Height

0.5

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

CD5 (Cris-1), CF568 conjugate, 0.1mg/mL
BNC680176-100 1x 100 µL

CD5 (Cris-1), CF568 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
CD8 (C8/1035), CF647 conjugate, 0.1mg/mL
BNC471035-100 1x 100 µL

CD8 (C8/1035), CF647 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
CD7 (T3-3A1), CF640R conjugate, 0.1mg/mL
BNC400978-100 1x 100 µL

CD7 (T3-3A1), CF640R conjugate, 0.1mg/mL

Sign In for Pricing
View Details
CD100 (Semaphorin-4D) (A8), CF568 conjugate, 0.1mg/mL
BNC680218-100 1x 100 µL

CD100 (Semaphorin-4D) (A8), CF568 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
CD86 (BU63), CF647 conjugate, 0.1mg/mL
BNC470193-500 1x 500 µL

CD86 (BU63), CF647 conjugate, 0.1mg/mL

Sign In for Pricing
View Details
Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF740 conjugate, 0.1mg/mL
BNC741820-100 1x 100 µL

Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF740 conjugate, 0.1mg/mL

Sign In for Pricing
View Details